A federal court dismissed a lawsuit against Cardiovascular Systems and approved a settlement between the company and a former salesman on July 11, Mass Device reports. The salesman alleged that Cardiovascular Systems used illegal tactics to increase sales of its orbiral atherectomy devices.

Former Valeant CEO Michael Pearson sold nearly five million shares and options for $96.8 million from June 30 through July 5, CNBC reports. Pearson left Valeant in late April after the company received criticism for significantly increasing the prices of its medications.

Mednax acquired Pediatric Cardiology Associates on July 11 in a cash transaction for an undisclosed amount.

The Centers for Medicare & Medicaid Services (CMS) revoked Theranos’ certification for a blood testing laboratory in California and prohibited the embattled company’s CEO Elizabeth Holmes from owning, operating or directing a laboratory for at least two years.

Since Joseph Papa took over as CEO of Valeant Pharmaceuticals, the company’s stock price has fallen by approximately 40 percent, the Wall Street Journal reports. The newspaper speculates one reason for the decrease may be Papa’s strategy while he ran Perrigo Co.

Shares of Esperion Therapeutics’ common stock have plunged this week after the company said the future of its investigational cholesterol-lowering drug remains murky. The FDA told the company that it might require a cardiovascular outcomes study before approving the medication, according to Forbes.

The Medicines Company completed its divestiture of three cardiovascular medications to Chiesi USA, Inc. on June 21, one month after the companies agreed to the deal.

Medtronic raised its quarterly cash dividend 13 percent on June 24 to $0.43 per ordinary share.